Hikma Pharmaceuticals PLC (HKMPF)
| Previous close | 0.00 |
| Open | 25.55 |
| Bid | 25.35 x 27000 |
| Ask | 26.51 x 38800 |
| Day's range | 25.55 - 26.07 |
| 52-week range | 21.28 - 27.00 |
| Volume | |
| Avg. volume | 280 |
| Market cap | 5.806B |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | 30.54 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.79 (3.04%) |
| Ex-dividend date | 15 Aug 2024 |
| 1y target est | N/A |
- PR Newswire
Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day
Hikma Pharmaceuticals in the US joined government officials and non-profit leaders today at a naloxone awareness and training event organized and hosted by Rep. Earl L. "Buddy" Carter of Georgia. This important educational event took place at Groves High School in Savannah, Ga. ahead of National Fentanyl Awareness and Prevention Day.
- PR Newswire
KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the shelf-life extension of KLOXXADO® (naloxone HCl) nasal spray 8mg from 24 to 36 months. KLOXXADO® packaging has been updated with 36-month dating, starting with product manufactured in March 2024.
- PR Newswire
Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today welcomed Dr. Rahul Gupta, Director of the White House Office of National Drug Control Policy (ONDCP), to its Columbus, Ohio manufacturing facility for a visit and important dialogue on the US opioid overdose epidemic and Hikma's and ONDCP's shared goal of expanding the availability and awareness of life-saving naloxone.
